[go: up one dir, main page]

MX2017006970A - Metodo basado en celulas para determinar la potencia de la defibrotida. - Google Patents

Metodo basado en celulas para determinar la potencia de la defibrotida.

Info

Publication number
MX2017006970A
MX2017006970A MX2017006970A MX2017006970A MX2017006970A MX 2017006970 A MX2017006970 A MX 2017006970A MX 2017006970 A MX2017006970 A MX 2017006970A MX 2017006970 A MX2017006970 A MX 2017006970A MX 2017006970 A MX2017006970 A MX 2017006970A
Authority
MX
Mexico
Prior art keywords
defibrotide
potency
determining
cellular
based method
Prior art date
Application number
MX2017006970A
Other languages
English (en)
Other versions
MX390823B (es
Inventor
Kumar Vijay
Ignoni Terenzio
Verga Claudio
Original Assignee
Gentium S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52000693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017006970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentium S R L filed Critical Gentium S R L
Publication of MX2017006970A publication Critical patent/MX2017006970A/es
Publication of MX390823B publication Critical patent/MX390823B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a métodos basados en células para determinar la actividad biológica de la defibrotida. En particular, la invención proporciona un método para evaluar la potencia de la defibrotida mediante la evaluación de la viabilidad de las células de mamífero en presencia de al menos un agente citotóxico y una o más concentraciones de defibrotida. Tales métodos son particularmente útiles para la estandarización de composiciones farmacéuticas que comprenden defibrotida.
MX2017006970A 2014-11-27 2015-11-23 Metodo basado en celulas para determinar la potencia de la defibrotida. MX390823B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195277.0A EP3026122A1 (en) 2014-11-27 2014-11-27 Cellular-based method for determining the potency of defibrotide
PCT/EP2015/077355 WO2016083297A1 (en) 2014-11-27 2015-11-23 Cellular-based method for determining the potency of defibrotide

Publications (2)

Publication Number Publication Date
MX2017006970A true MX2017006970A (es) 2018-03-01
MX390823B MX390823B (es) 2025-03-21

Family

ID=52000693

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006970A MX390823B (es) 2014-11-27 2015-11-23 Metodo basado en celulas para determinar la potencia de la defibrotida.
MX2022003399A MX2022003399A (es) 2014-11-27 2017-05-26 Metodo basado en celulas para determinar la potencia de la defibrotida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003399A MX2022003399A (es) 2014-11-27 2017-05-26 Metodo basado en celulas para determinar la potencia de la defibrotida.

Country Status (19)

Country Link
US (3) US10393731B2 (es)
EP (4) EP3026122A1 (es)
JP (3) JP6700276B2 (es)
KR (2) KR20220104070A (es)
CN (1) CN107109458B (es)
AU (2) AU2015352743B2 (es)
BR (1) BR112017011012B1 (es)
CA (1) CA2968608C (es)
DK (2) DK3120153T3 (es)
ES (2) ES2972368T3 (es)
FI (1) FI3748358T3 (es)
IL (2) IL252484B (es)
MX (2) MX390823B (es)
PL (1) PL3120153T3 (es)
PT (1) PT3120153T (es)
RU (1) RU2729628C2 (es)
SG (1) SG11201704015RA (es)
WO (1) WO2016083297A1 (es)
ZA (1) ZA201703385B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007617A (zh) 2010-11-12 2017-08-04 真蒂奥姆责任有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
SG11201408481UA (en) 2012-06-22 2015-01-29 Gentium Spa Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) * 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN111796086A (zh) * 2020-07-03 2020-10-20 同济大学 一种个人护理品急慢性剂量-效应关系表征方法
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2812943C3 (de) 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1170215B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US4693134A (en) 1985-06-20 1987-09-15 Excelermatic Inc. High-powered vehicle drive train
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US5231006A (en) 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US4753221A (en) 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
IT1223322B (it) 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
JP2907447B2 (ja) 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US5624912A (en) 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH08127539A (ja) 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
WO1996016987A1 (en) 1994-11-30 1996-06-06 Chugai Seiyaku Kabushiki Kaisha Thrombocytotic factor
DE69733694T2 (de) 1996-07-10 2006-07-06 Muramatsu, Takashi, Nagoya Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
AU754242B2 (en) 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
JP2002512508A (ja) 1997-05-30 2002-04-23 マクギル・ユニヴァーシティ Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
GB9719161D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
ATE311907T1 (de) 1999-06-08 2005-12-15 Gentium Spa Anwendung von komplexen von kationischen liposomen und polydeoxyribonukleotiden wie arzneimitteln
EP1147777A1 (en) 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
CA2426540A1 (en) 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
CA2430341A1 (en) * 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
CA2433225A1 (en) 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1325962A1 (en) * 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
AU2003225724A1 (en) 2002-03-11 2003-09-29 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
MXPA04011941A (es) 2002-05-31 2005-07-26 Univ Regensburg Klinikum Metodo para la proteccion de celulas endoteliales y epiteliales durante la quimioterapia.
US20050215498A1 (en) 2002-05-31 2005-09-29 Guenther Eissner Method for the protection of endothelial and epithclial cells during chemotherapy
MXPA05000272A (es) 2002-07-01 2005-09-20 Savient Pharmaceuticals Inc Anticuerpos y usos de ellos.
CA2501719C (en) 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
US7723127B2 (en) * 2005-03-03 2010-05-25 Novx Systems Inc. Immunoassay with extended dynamic range
AU2006222044A1 (en) 2005-03-03 2006-09-14 Gentium Spa Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
JP2010533478A (ja) * 2007-07-13 2010-10-28 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの阻害剤の基質特異性を同定するための組成物および方法
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
US20110191868A1 (en) * 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
US20120093922A1 (en) 2009-04-29 2012-04-19 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN107007617A (zh) 2010-11-12 2017-08-04 真蒂奥姆责任有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
SG11201408481UA (en) 2012-06-22 2015-01-29 Gentium Spa Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide

Also Published As

Publication number Publication date
CA2968608A1 (en) 2016-06-02
EP4368990A3 (en) 2024-08-07
KR20170094790A (ko) 2017-08-21
AU2015352743B2 (en) 2020-10-15
EP3120153B1 (en) 2020-08-19
JP6700276B2 (ja) 2020-05-27
RU2017122187A (ru) 2018-12-28
KR20220104070A (ko) 2022-07-25
IL277068A (en) 2020-10-29
AU2015352743A1 (en) 2017-06-08
US10393731B2 (en) 2019-08-27
IL252484B (en) 2020-09-30
NZ731825A (en) 2024-02-23
SG11201704015RA (en) 2017-06-29
ES2972368T3 (es) 2024-06-12
US20200057051A1 (en) 2020-02-20
IL277068B (en) 2021-10-31
EP4368990A2 (en) 2024-05-15
RU2729628C2 (ru) 2020-08-11
DK3120153T3 (da) 2020-11-09
MX2022003399A (es) 2022-04-18
AU2020250225A1 (en) 2020-11-05
US20230194502A1 (en) 2023-06-22
EP3026122A1 (en) 2016-06-01
BR112017011012B1 (pt) 2024-01-16
ES2831834T3 (es) 2021-06-09
JP2022160596A (ja) 2022-10-19
EP3748358A1 (en) 2020-12-09
JP2020058360A (ja) 2020-04-16
KR102421677B1 (ko) 2022-07-18
RU2017122187A3 (es) 2019-01-17
BR112017011012A2 (pt) 2018-02-14
DK3748358T3 (da) 2024-02-26
CA2968608C (en) 2023-09-05
AU2020250225B2 (en) 2022-06-30
FI3748358T3 (fi) 2024-02-14
ZA201703385B (en) 2018-08-29
JP2017535277A (ja) 2017-11-30
PT3120153T (pt) 2020-10-20
CN107109458A (zh) 2017-08-29
EP3120153A1 (en) 2017-01-25
EP3748358B1 (en) 2023-12-27
CN107109458B (zh) 2021-10-26
MX390823B (es) 2025-03-21
WO2016083297A1 (en) 2016-06-02
IL252484A0 (en) 2017-07-31
US20170322199A1 (en) 2017-11-09
PL3120153T3 (pl) 2021-02-08

Similar Documents

Publication Publication Date Title
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2018003353A (es) Terapias con celulas cart con una eficacia mejorada.
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
MX2015014892A (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
EP4368992A3 (en) Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2016016076A (es) Composiciones de celulas t mejoradas.
BR112016015105A2 (pt) Conjugados var2csa-droga
EP2832851A4 (en) IMMORTALIZED STEM CELLS AND MEDICAL COMPOSITION AND MEDICAMENT WITH A PRODUCT THEREOF AS AN ACTIVE SUBSTANCE
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
CR20170234A (es) Composiciones de antibiótico
MX2016015462A (es) Composicion y metodo para estabilizar y mantener la viabilidad de los microorganismos resistentes.
MX2017006970A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
DOP2016000253A (es) Nuevos compuestos
CO2017000056A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
AR099500A1 (es) Composición para el desmucilaginado enzimático de aceite
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
BR112017003167A2 (pt) método in vitro e aparelho para análise do comportamento de substâncias em ambiente fisiológico simulado
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
MX2014006088A (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.